16.03.2022 - RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP), ( Helix or the Company ), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary .
RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology
RICHMOND HILL, ON / ACCESSWIRE / December 31, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and